William G. Kaelin
Department of Medical Oncology
Dana-Farber Cancer Institute and Brigham and Women's Hospital
Harvard Medical School
Boston
USA
Name/email consistency: high
- Influence of metabolism on epigenetics and disease. Kaelin, W.G., McKnight, S.L. Cell (2013)
- New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Kaelin, W.G. Ann. N. Y. Acad. Sci. (2010)
- Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Kaelin, W.G. Cancer (2009)
- SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Kaelin, W.G. Cancer. Cell (2009)
- Synthetic lethality: a framework for the development of wiser cancer therapeutics. Kaelin, W.G. Genome. Med (2009)
- The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Kaelin, W.G. Nat. Rev. Cancer (2008)
- Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Kaelin, W.G., Ratcliffe, P.J. Mol. Cell (2008)
- Kidney cancer: now available in a new flavor. Kaelin, W.G. Cancer. Cell (2008)
- The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Kaelin, W.G. Clin. Cancer Res. (2007)
- Von Hippel-Lindau disease. Kaelin, W.G. Annual. Review. Pathology (2007)
- Proline hydroxylation and gene expression. Kaelin, W.G. Annu. Rev. Biochem. (2005)
- The concept of synthetic lethality in the context of anticancer therapy. Kaelin, W.G. Nat. Rev. Cancer (2005)
- The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Kaelin, W.G. Biochem. Biophys. Res. Commun. (2005)
- The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin, W.G. Clin. Cancer Res. (2004)
- E2F1 as a target: promoter-driven suicide and small molecule modulators. Kaelin, W.G. Cancer Biol. Ther. (2003)
- The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. Kaelin, W.G. J. Am. Soc. Nephrol. (2003)
- How oxygen makes its presence felt. Kaelin, W.G. Genes Dev. (2002)
- Molecular basis of the VHL hereditary cancer syndrome. Kaelin, W.G. Nat. Rev. Cancer (2002)
- The emerging p53 gene family. Kaelin, W.G. J. Natl. Cancer Inst. (1999)
- Functions of the retinoblastoma protein. Kaelin, W.G. Bioessays (1999)
- Taking aim at novel molecular targets in cancer therapy. Kaelin, W.G. J. Clin. Invest. (1999)
- Choosing anticancer drug targets in the postgenomic era. Kaelin, W.G. J. Clin. Invest. (1999)
- The p53 gene family. Kaelin, W.G. Oncogene (1999)
- Another p53 Doppelgänger?. Kaelin, W.G. Science (1998)
- Functions of the von Hippel-Lindau tumour suppressor protein. Kaelin, W.G., Iliopoulos, O., Lonergan, K.M., Ohh, M. J. Intern. Med. (1998)
- Alterations in G1/S cell-cycle control contributing to carcinogenesis. Kaelin, W.G. Ann. N. Y. Acad. Sci. (1997)